Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase 3 Trial for Chronic Migraine Prevention
![GlobeNewswire](../../../Content/images/providers/GN.png)
ALDER BIOPHARMACEUTICALS INC (ALDR)
Last alder biopharmaceuticals inc earnings: 8/6 04:07 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.alderbio.com/node/5806
Company Research
Source: GlobeNewswire
-- Highly statistically significant results with rapid prevention beginning Day One, 50%, 75%, 100% responder rates by month one sustained for three months -- -- 15% of patients had no migraines for a full three months -- -- Conference call and webcast to be held today, January 8, at 8:30 a.m. ET -- BOTHELL, Wash., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that eptinezumab, its lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide (CGRP), met the primary endpoint in its pivotal Phase 3 PROMISE 2 clinical trial with very high statistical significance vs. placebo (pDay One (p “These clinically significant data clearly demons
Show less
Read more
Impact Snapshot
Event Time:
ALDR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDR alerts
High impacting ALDER BIOPHARMACEUTICALS INC news events
Weekly update
A roundup of the hottest topics